Advertisement
Table 2 SVR12 by the different duration of treatment, regimens, genotypes, treatment history, and the presence or absence of cirrhosis
| Response | SVR12 (N = 1358) | Heterogeneity | Pb-value | Studies | ||
|---|---|---|---|---|---|---|
| Total, n/N | Rate (95%CI) | I2(%) | P a | |||
| Overall | 1296/1358 | 96.3 (95.1–97.4) | 42 | 0.08 | 10 | |
| By the different duration of treatment | 0.9237 | |||||
| 12 weeks | 394/415 | 96.2 (92.6–98.8) | 41 | 0.13 | 6 | |
| 24 weeks | 52/55 | 96.6 (82.5–100.0) | 65 | 0.09 | 2 | |
| By regimens | 0.8563 | |||||
| OBV/PTV/r ± DSV ± RBV | 811/850 | 96.4 (94.8–97.7) | 25 | 0.21 | 10 | |
| OBV/PTV/r ± RBV | 152/159 | 98.9 (95.3–100.0) | 0.0 | 0.99 | 3 | |
| By genotypes | 0.8424 | |||||
| 1 | 1025/1076 | 96.2 (94.8–97.4) | 38 | 0.13 | 8 | |
| 4 | 149/156 | 98.8 (95.1–100.0) | 0 | 0.99 | 3 | |
| By treatment history | 0.8281 | |||||
| TN patients | 423/440 | 96.8 (94.8–98.5) | 41 | 0.15 | 5 | |
| TE patients | 273/285 | 98.9 (96.4–100.0) | 50 | 0.09 | 5 | |
| By the presence or absence of cirrhosis | 0.3887 | |||||
| Cirrhosis | 218/230 | 97.8 (94.6–99.8) | 43 | 0.12 | 6 | |
| Non-cirrhosis | 899/935 | 96.7 (95.3–97.8) | 20 | 0.28 | 6 | |
